PDL BIOPHARMA, INC. - 69329Y104
Detailed investor-level table based on 13F positions.
Methodology:
Market value and % of portfolio use SEC reported VALUE ($000).
For PUT/CALL positions this reflects reported underlying exposure, not premium cash paid/received.
Details.
Rows: 0
| Investor | History | Status | Shares held | Market value ($000) | % of portfolio | Previous % | Rank | Change in shares | % change in shares | Source | Date reported |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RHUMBLINE ADVISERS | History | No change | 612 | 1 | 0.0% | 0.0% | 1 | 0 | 0.0% | Q3 2026 | Nov 10, 2026 |
| Diversified Trust Co | History | Closed out | 0 | 0 | — | 0.0% | — | -11,554 | -100.0% | Q3 2026 | Nov 06, 2026 |
| Financial Gravity Companies, Inc. | History | No change | 13 | 0 | — | — | — | 0 | 0.0% | Q2 2026 | Aug 05, 2026 |
| Westside Investment Management, Inc. | History | No change | 500 | 0 | — | — | — | 0 | 0.0% | Q3 2026 | Nov 02, 2026 |
| Argent Trust Co | History | No change | 41,405 | 0 | — | — | — | 0 | 0.0% | Q3 2026 | Nov 09, 2026 |
| WELLINGTON-ALTUS USA INC. | History | No change | 275 | 0 | — | — | — | 0 | 0.0% | Q2 2026 | Sep 17, 2026 |